← Back to Clinical Trials
Recruiting NCT06935812

NCT06935812 Comparison of the Effects of Bimanual, Finger and VR Exercises in PwMCI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06935812
Status Recruiting
Phase
Sponsor Eastern Mediterranean University
Condition Mild Cognitive Impairment
Study Type INTERVENTIONAL
Enrollment 106 participants
Start Date 2025-04-29
Primary Completion 2026-09-24

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Bimanual ExerciseFinger ExerciseVirtual Reality

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 106 participants in total. It began in 2025-04-29 with a primary completion date of 2026-09-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Mild Cognitive Impairment (MCI) is defined as an impairment in a single cognitive function, usually memory, other than normal cognitive decline with age, that does not fulfil dementia criteria. Finger movements have been shown to stimulate the sensory-motor and cognitive parts of the cerebral cortex, as well as the supplementary motor area, Broca's area, premotor cortex, and prefrontal cortex, all of which contribute to movement skills. Asymmetrical hand and finger movements done concurrently were proven to improve cognitive processes and cerebral blood flow more than movements performed with one hand.

Eligibility Criteria

Inclusion Criteria: * Participants who are between 50-75 years of age * Individuals diagnosed with MCI by a geriatrician according to DSM-5 criteria, * Who has the Montreal Cognitive Assessment score between 13-26, * Who has the Quick Mild Cognitive Impairment screen score between 48-67, * Who has Instrumental Activities of Daily Living Scale score ≥6/8, * Who says yes to "Do you have a memory problem?" question, * Who can walk independently without using any walking aids Exclusion Criteria: * Participants who have any musculoskeletal disorders that may cause balance and gait disorders, * Who have central or peripheral neurological diseases (eg. stroke, Parkinson's disease or polyneuropathies), * Who are using psychiatric drugs that may affect psychiatric disease and/or cognitive performance (Using nonsteroidal anti-inflammatory drugs more than three times a week, which may affect cognitive functions, using gingko biloba and antioxidant supplements (for example, coenzyme Q10 and alpha-lipoic acid)), * Who has daltonism and * Who attends any exercise program last 6 months will not be included in this study.

Contact & Investigator

Central Contact

Betül Fatma Bilgin, MSc PT

✉ betulll_96@hotmail.com

📞 3926303011

Principal Investigator

Betül Fatma Bilgin, MSc PT

PRINCIPAL INVESTIGATOR

Eastern Mediterranean University

Frequently Asked Questions

Who can join the NCT06935812 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Mild Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06935812 currently recruiting?

Yes, NCT06935812 is actively recruiting participants. Contact the research team at betulll_96@hotmail.com for enrollment information.

Where is the NCT06935812 trial being conducted?

This trial is being conducted at Famagusta, Cyprus.

Who is sponsoring the NCT06935812 clinical trial?

NCT06935812 is sponsored by Eastern Mediterranean University. The principal investigator is Betül Fatma Bilgin, MSc PT at Eastern Mediterranean University. The trial plans to enroll 106 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology